The latest financial statement is for the quarter ending 2025-12-31.
| Cash Flow | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 |
|---|---|---|---|---|
| Net earnings | 38,009 | 38,185 | -17,678 | 22,588 |
| Depreciation and amortization | 24,709 | 24,340 | 27,111 | 27,571 |
| Costs recognized on sale of acquired inventory | - | - | 197 | 181 |
| Deferred income taxes | -72 | 5,275 | -32,282 | -5,408 |
| Stock-based compensation expense | 13,958 | 11,682 | 4,550 | 11,391 |
| Fair value adjustment to contingent consideration payable | - | - | - | 0 |
| Fair value adjustment on available-for-sale investments | - | - | - | 0 |
| (gain) loss on equity method investment | 110 | 294 | 1,107 | -589 |
| (gain) loss on investments | -2,017 | 2,054 | - | - |
| Asset impairment restructuring | 3,253 | - | 11,351 | 120 |
| Leases, net | -868 | -912 | 183 | 10 |
| Impairment (recovery) of assets held-for-sale | - | - | 84,158 | -3,655 |
| Recovery of assets held-for-sale | 0 | 6,789 | - | - |
| Other operating activity | -338 | 1,001 | 148 | 222 |
| Trade accounts and other receivables, net | -941 | -22,392 | -28,861 | 15,669 |
| Inventories | 1,939 | 14,002 | 6,604 | -173 |
| Prepaid expenses | -2,875 | -380 | 7,155 | 6,812 |
| Trade accounts payable, accrued expenses, contract liabilities, and other | -5,992 | -2,115 | -13,315 | -610 |
| Salaries, wages and related accruals | 1,393 | -22,101 | 3,402 | 8,124 |
| Income taxes payable | 4,575 | -27,403 | 16,381 | 2,305 |
| Net cash provided by (used in) operating activities | 82,411 | 27,585 | 98,201 | 41,120 |
| Proceeds from sale of available-for-sale investments | - | - | 0 | 0 |
| Purchases of available-for-sale investments | - | - | - | 0 |
| Additions to property and equipment | 5,921 | 5,363 | 4,890 | 10,123 |
| Acquisitions, net of cash acquired | - | - | - | 0 |
| Distributions from wilson wolf | 0 | 101 | - | 1,250 |
| Distributions from (investments in) wilson wolf | - | - | 7,291 | - |
| Investment in spear bio | - | - | 0 | 0 |
| Proceeds from sale of assets held-for-sale | 0 | 4,617 | 658 | 0 |
| Net cash provided by (used in) investing activities | -5,921 | 605 | 406 | -8,873 |
| Cash dividends | 12,470 | 12,444 | 12,387 | 12,580 |
| Proceeds from stock option exercises | 4,739 | 23,495 | 6,226 | 14,872 |
| Repurchases of common stock | 0 | 24 | 100,057 | 100,046 |
| Borrowings under line-of-credit agreement | - | - | 66,000 | 38,000 |
| Repayments of long-term debt | 40,000 | 46,000 | 50,000 | 8,000 |
| Taxes paid on rsus and net share settlements | 1,255 | 9,231 | 234 | 291 |
| Net cash provided by (used in) financing activities | -48,986 | -44,204 | -90,452 | -68,045 |
| Effect of exchange rate changes on cash and cash equivalents | 413 | -1,210 | 13,361 | -1,081 |
| Net change in cash and cash equivalents | 27,917 | -17,224 | 21,516 | -36,879 |
| Cash and cash equivalents at beginning of period | 144,962 | 162,186 | 140,670 | 177,549 |
| Cash and cash equivalents at end of period | 172,879 | 144,962 | 162,186 | 140,670 |
BIO-TECHNE Corp (TECH)
BIO-TECHNE Corp (TECH)